A Study of the Efficacy and Safety of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes

Conditions

• Diabetes Mellitus, Type 2

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Dulaglutide — DRUG
  Administered SC

Study Details

The purpose of this study is to evaluate the efficacy and safety of investigational doses of once weekly dulaglutide when added to metformin in participants with type 2 diabetes with inadequate blood sugar control.

Key Dates

Start date

Apr 5, 2018

Status verified

Dec 2019

Primary completion

May 28, 2019

Completion

Oct 10, 2019

Study Design

Enrollment

1,842 participants (actual)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Active Comparator: Dulaglutide 1.5 mg
  Dulaglutide 1.5 mg administered subcutaneously (SC) once a week.
• Experimental: Dulaglutide 3 mg
  Dulaglutide 3 mg administered SC once a week.
• Experimental: Dulaglutide 4.5 mg
  Dulaglutide 4.5 mg administered SC once a week.

Primary Outcome Measure

Change in Hemoglobin A1c (HbA1c) From Baseline [ Time Frame: Baseline, Week 36 ]

Locations (72)

Find similar trials in Chandler, AZ

Related Studies

• Pre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT)
  Recruiting · The University of Texas Health Science Center at San Antonio · San Antonio, Texas
• Tau PET Imaging in the Northern Manhattan Study of Metabolism and Mind.
  PHASE2 · Enrolling By Invitation · Columbia University · New York, New York
• Phenotyping Genetic Risk for Type 2 Diabetes
  Recruiting · University of Pennsylvania · Philadelphia, Pennsylvania
• Use of CGM in Kidney Transplant Recipients
  Recruiting · University of California, Davis · Sacramento, California